XTLB
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
No Graham Number available; valuation is disconnected from earnings.
- P/S ratio of 5.98 is high for a company with negative gross margins
- PEG ratio of 2.27 suggests overvaluation relative to growth
Growth metrics are largely N/A or based on outdated 2016 data.
- Small EPS growth improvement
- No recent revenue growth data
- Extreme operational inefficiency
Long-term price performance is overwhelmingly bearish.
- 5-year return of -81.5%
- Consistent quarterly losses
Altman Z-Score not provided, but liquidity ratios signal distress.
- Piotroski F-Score 3/9 (Weak)
- Current Ratio < 1.0
- ROE of -577.13%
Dividend Strength 0/100.
- No dividend history
- Zero payout capacity
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for XTLB and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
Primary
|
-81.5% | -49.8% | -49.8% | -50.6% | -5.8% | -1.2% |
|
XAIR
Beyond Air, Inc.
Peer
|
-99.5% | -99.5% | -86.8% | -73.7% | -26.9% | +22.9% |
|
SNYR
Synergy CHC Corp.
Peer
|
-94.2% | -94.2% | -78.9% | -80.5% | -60.5% | -8.7% |
|
BIAF
bioAffinity Technologies, Inc.
Peer
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2024
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
XTLB
XTL Biopharmaceuticals Ltd.
|
BEARISH | $5.78M | - | -577.1% | -% | $2.44 | |
|
XAIR
Beyond Air, Inc.
|
BEARISH | $5.76M | - | -240.2% | -% | $0.55 | Compare |
|
SNYR
Synergy CHC Corp.
|
BEARISH | $5.93M | - | -% | -40.6% | $0.52 | Compare |
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | Compare |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning XTLB from our newsroom.